uptake of a new cervical cancer prevention technology in a medicaid population
DESCRIPTION
Uptake of a New Cervical Cancer Prevention Technology in a Medicaid Population. Rebecca Anhang Price AcademyHealth Annual Research Meeting June 10, 2008. Funding: Foundation for Informed Medical Decision Making; Novartis Fellowship. Background: Cervical Cancer and Human Papillomavirus (HPV). - PowerPoint PPT PresentationTRANSCRIPT
Uptake of a New Cervical Cancer Prevention Technology in a
Medicaid Population
Rebecca Anhang PriceAcademyHealth Annual Research
MeetingJune 10, 2008
Funding: Foundation for Informed Medical Decision Making; Novartis Fellowship
Background: Cervical Cancer and Human Papillomavirus (HPV)
• Virtually all cervical cancers are caused by carcinogenic or “high risk” strains of human papillomavirus (HPV).
• In 2000, the FDA approved a DNA test that detects carcinogenic types of HPV. – Two main uses:
• Reflex testing for equivocal Pap results (ASC-US or atypical squamous cells of uncertain significance)
• Primary screening for women age 30+
Background:Timeline of Clinical Guideline Releases
Initial FDA approval of HPV testing for triage of Pap test results deemed ASC-US
Consensus Guidelines by the American Society for Colposcopy and Cervical Pathology (ASCCP) released
American Cancer Society (ACS) guidelines released
U.S. Preventive Services Task Force guidelines released
American College of Obstetricians and Gynecologists guidelines released
Digene’s DTC campaign for HPV DNA testing launched
March
2000
April
2002
November
2002
January
2003
March
2003
August
2003
March2005
FDA approves expanded indication for HPV DNA testing: Primary screening of women over age 30, in conjunction with the Pap test
April2006
June2006
Merck & Co.’s DTC campaign for HPV awareness launched
FDA approves Merck & Co.’s HPV vaccine
Feb2004
Co-sponsored Interim Guidance from National Cancer Institute, ASCCP, ACS published
Research Objectives
• To evaluate the impact of clinical guidelines on the uptake of HPV DNA tests.
• To identify patient and provider characteristics associated with overall and clinically appropriate HPV DNA test use.
Methods: Data
• Florida Medicaid claims database, July 2001 – June 2006.
• Inclusion criteria:– Age 21 to 64– Eligible through TANF/AFDC, family planning or pregnancy – Continuously enrolled for at least 12 months– No hysterectomy during study period
• Resulting dataset included 310,427 cervical screening test claims and 13,550 HPV DNA test claims for 415,239 Medicaid enrollees.
Methods: Analysis
• Dependent Variables: – HPV DNA test (given receipt of cervical cancer screening test)– Appropriate test (given receipt of HPV DNA test)
• Independent Variables of Interest:– Time variables (time trend, dummy dates for clinical guideline releases)– Patient race/ethnicity– Provider specialty
• Other Covariates:– Patient age, ASC-US diagnosis, district of residence, total months
enrolled – Pathology lab volume
• Estimation approach:– Generalized estimating equations with logit link.– Robust standard error estimates to account for patient clustering within
providers.
Results: Sample Characteristics
* Turn 30 at some point during the study period. † ASC-US diagnosis can only be determined among those for whom a cervical screening test claim is filed.
CharacteristicBeneficiaries(n = 415,239)
Age, years (%) 21 – 29 30 – 64*
46.7153.29
Race/ethnicity (%) White Black Hispanic Other
40.3734.1322.90 2.60
Diagnosis (%)† Atypical squamous cells of uncertain significance (ASC-US)
1.15
Screening Behavior (%) Received any cervical screening test Received an HPV DNA test
40.02 2.87
Results: HPV Test Use, July 2001 – June 2006
050
100150
200250300
350400
450500
Jul-
01
No
v-0
1
Ma
r-0
2
Jul-
02
No
v-0
2
Ma
r-0
3
Jul-
03
No
v-0
3
Ma
r-0
4
Jul-
04
No
v-0
4
Ma
r-0
5
Jul-
05
No
v-0
5
Ma
r-0
6
# o
f T
es
ts
Results: Appropriate HPV Test Use, July 2001 – June 2006
0%
20%
40%
60%
80%
100%
Jul-0
1
Nov
-01
Mar
-02
Jul-0
2
Nov
-02
Mar
-03
Jul-0
3
Nov
-03
Mar
-04
Jul-0
4
Nov
-04
Mar
-05
Jul-0
5
Nov
-05
Mar
-06
% o
f H
PV
Tes
ts t
hat
are
Clin
ical
ly A
pp
rop
riat
e
Results: Effects of Guidelines on HPV Test Use
GEE Parameter Estimates(n = 310,427, 13,550 HPV DNA tests)
Time trend (by month) 0.007***
Clinical guidelines
Release of American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines (4/02)
0.882***
Release of American Cancer Society (ACS) guidelines (11/02)
0.160**
FDA approval for 30+ (3/03) 0.193**
Release of American College of Obstetricians and Gynecologists (ACOG) guidelines (8/03)
0.250***
Release of co-sponsored interim guidance (2/04)
-0.038
*p<0.05; **p<0.01; ***p<0.0001Models also control for patient, provider and lab characteristics, as well as the fixed effects of residence in each of 11 Medicaid districts in Florida, and total number of months enrolled in Medicaid.
Results: Differential Diffusion of HPV Test Use by Race/Ethnicity and Provider Specialty
Note: Predicted probabilities from multivariate models including time trend, important dates, patient age, race/ethnicity, and ASC-US diagnosis, provider specialty, pathology lab volume, fixed effects of residence in each of 11 Medicaid districts in Florida, and total number of months enrolled in Medicaid. Models also include interaction effects for monthly time trend * patient race/ethnicity and provider specialty * patient race/ethnicity.
Predicted Probabilities of HPV Test Use, by Provider Specialty and Patient Race/Ethnicity,
July 2001 - June 2006
00.020.040.060.080.1
0.120.140.160.180.2
Jul-0
1
Nov
-01
Mar
-02
Jul-0
2
Nov
-02
Mar
-03
Jul-0
3
Nov
-03
Mar
-04
Jul-0
4
Nov
-04
Mar
-05
Jul-0
5
Nov
-05
Mar
-06
OBGYN Black
OBGYN Hispanic
OBGYN White
PCP Black
PCP Hispanic
PCP White
Results: Predictors of Appropriate HPV Test Use
• Clinical guidelines were not consistently associated with appropriate HPV test use.
• Obstetricians/gynecologists were more likely than primary care providers to administer the test appropriately.
Conclusions
• Uptake of the HPV DNA test was sustained by introduction of multiple sets of clinical guidelines. – Guidelines did not consistently promote appropriate
use.
• Racial/ethnic disparities in HPV DNA test use resolved within three years of the test’s introduction.– Early adoption of testing by
obstetricians/gynecologists helped to close the gap.
Implications
• Release of clinical guidelines is associated with increases in use of a new technology. – However, guidelines may not be associated
with increases in appropriate use.
• Adoption of new technologies may initially occur more slowly in minority groups.– However, these groups can catch up, assisted
by early guideline adherence by specialists.